| TCGA cohort | GSE17538 | P-value |
---|---|---|---|
Number [n] | 428 | 231 | NA |
Death [n(%)] | 98 (22.9) | 93 (40.3) | <Â 0.001 |
Total survival time (mean ± SD, month) | 29.8 ± 25.6 | 47.6 ± 30.6 | < 0.001 |
Survival time for dead patients (month) | 23.3 ± 22.7 | 26.8 ± 22.0 | < 0.001 |
Survival time for living patients (month) | 31.7 ± 26.1 | 61.7 ± 27.5 | < 0.001 |
Age (mean ± SD, year) | 66.5 ± 13.0 | 64.8 ± 13.4 | 0.100 |
Male [(n)%] | 230 (53.7) | 121 (52.4) | 0.739 |
AJCC stage (IV/III/II/I/NA) | 60/124/163/70/11 | 56/75/72/28/0 | <Â 0.001 |
AJCC PT (T1/T0/NA) | 51/294/72/11/0 | NA | NA |
AJCC PN (N2/N1/N0/NA) | 76/103/249/0 | NA | NA |
AJCC PM (M2/M1/M0/NA) | 47/60/315/6 | NA | NA |
Lymphovascular invasion (yes/no/NA) | 148/237/43 | NA | NA |
Vascular invasion (yes/no/NA) | 89/281/58 | NA | NA |
Residual tumor (3/2/1/0/NA) | 23/21/4/307/73 | NA | NA |
Perineural invasion (yes/no/NA) | 45/126/257 | NA | NA |
Grade (1/0/NA) | NA | 55/144/32 | NA |